Gemcitabine
- IVGemcitabine
Mechanism of Action
- Converted intracellularly into diphosphate and triphosphate forms. The diphosphate form inhibits ribonucleotide reductase resulting in reduced intracellular deoxynucleotides, while the triphosphate form is incorporated into DNA and disrupts DNA polymerase activity.
Clinical Use
Indications
- Certain haematologic organ malignancies, as guided by cancer specialists and local guidelines.
- Adverse Effects
- Bone marrow suppression - leucopaenia / thrombocytopaenia / anaemia
- Anxiety
- Tachycardia
- Headache / dizziness
- Nausea / vomiting / anorexia / diarrhoea
- Arthralgia / myalgia